Micronoma was founded by leaders in microbiome research with the goal of revolutionizing and advancing early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are identified and addressed by their clinicians at the earliest stage, for a better chance to live longer, healthier lives.
Sandrine Miller-Montgomery, Pharm.D., Ph.D. is the Co-Founder, President and CEO of Micronoma, the first cancer-detection company using liquid biopsy technology to detect and predict cancer by analyzing the microbial signal with clinical-grade accuracy at an early stage of the disease. Prior to this, she was executive director of UC San Diego’s Center for Microbiome Innovation (CMI) that she co-led with renowned microbiome researcher, Dr. Rob Knight. There, she established a world-class team focused on expanding industry and academic collaborations in the field of microbiome research that resulted in raising more than $18M of financial support through key partnerships toward application of this science to AI, Diet and nutrition aging, environment, human disease understanding and more. Before this three-year detour in academia, she had worked in large biotech and multinational companies the life science industry) as well as start-ups. She has assumed different responsibilities from R&D director to leading sales and marketing organizations. She excels at preparing companies for successful exits as shown by her work at Helixis, acquired by Illumina, and MO BIO Labs acquired by QIAGEN. A scientist at heart and with a drive to bring life-changing innovation to the masses, Sandrine has found her passion in leading Micronoma, committed to improving the lives of all involved in cancer diagnosis.
Greg Poore, is the co-founder and Chief Analytic Officer (CAO) of Micronoma, and the co-inventor of its method to diagnose cancer using microbial nucleic acids. A passionate entrepreneur with a heart to help others, he founded his first non-profit corporation at age 18 to provide educational opportunities to underprivileged and foster youth in South Florida, and then co-founded his first medtech company at age 22 to help his friends better manage their asthma condition. This medtech company, Vigor Medical Systems, has since raised ~$1M in funding to produce its patented low-cost spirometer, of which Greg is a co-inventor, and a population-scale respiratory disease management platform. Micronoma represents his third corporation at age 25 and was strongly inspired by the unexpected stage IV diagnosis and tragic sudden loss of his grandmother to pancreatic cancer while attending college. Academically, Greg is an International Baccalaureate recipient (2012), Kiwanis International Jacobson Scholar (2012-2016), two-time Kenan Fellow at The Scripps Research Institute (2011, 2013), Pratt School of Engineering Fellow (2015), National Academy of Engineering Grand Challenge Scholar (2015), summa cum laude graduate from Duke University with a B.S.E. in Biomedical Engineering (2016), and a fully-funded double doctorate candidate in UC San Diego’s Medical Scientist Training Program (MSTP, 2016-Present). He has co-authored peer-reviewed accepted papers in high-impact journals, including Nature, Cell, and Nature Genetics, has an issued patent with several others under review, and was awarded NIH fellowship funding for his research on the cancer microbiome (F30, 2019-Present). Working at the nexus of medicine, science, and entrepreneurship, it is his overall goal to develop innovative and translational technologies that improve the diagnosis, management, and treatment of chronic diseases.
Rob Knight, Ph.D. is the co-Founder of Micronoma and co-inventor of Oncobiota™, the founding Director of the Center for Microbiome Innovation and Professor of Pediatrics and Computer Science & Engineering at UC San Diego. Before that, he was Professor of Chemistry & Biochemistry and Computer Science in the BioFrontiers Institute of the University of Colorado at Boulder, and an HHMI Early Career Scientist. He is a Fellow of the American Association for the Advancement of Science and of the American Academy of Microbiology. He was recently honored with the 2019 NIH Director’s Pioneer Award for his microbiome research. He received the 2017 Massry Prize, often considered a predictor of the Nobel Prize. In 2015 he received the Vilceck Prize in Creative Promise for the Life Sciences. He is the author of “Follow Your Gut: The Enormous Impact of Tiny Microbes” (Simon & Schuster, 2015), coauthor of “Dirt is Good: The Advantage of Germs for Your Child’s Developing Immune System (St. Martin’s Press, 2017) and spoke at TED in 2014. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline (cited over 17,000 times as of this writing) and UniFrac (cited over 7000 times including its web interface). He is co-founder of the Earth Microbiome Project and the American Gut Project. In addition to his work with microbiome and early-cancer detection, his work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease, has enhanced our understanding of microbes in environments ranging from the oceans to the tundra, and made high-throughput sequencing techniques accessible to thousands of researchers around the world.
Eddie Adams, Ph.D.
Chief Scientific Officer
Chief Operating Officer
Magda Marquet, Ph.D.
Chairman of the Board; Co-Founder, Ajinomoto Althea & AltheaDx
Scientific Advisory Board
Martin J. Blaser, M.D.
Chairman, Professor of Medicine and Pathology and Director of the Center for Advanced Biotechnology and Medicine, and holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University.
Leena Das-Young, Pharm. D.
C-suite executive for biopharma in oncology, infectious disease, liquid biopsy, and product development in complex disease and precision medicine settings, including executive roles at both Pfizer and Guardant Health.
Ravid Straussman, M.D., Ph.D.
Principal Investigator at the Weizmann Institute where his research is focused on understanding the roles of the tumor microenvironment and the tumor microbiome on resistance to cytotoxic, targeted, and immune-mediated anti-cancer therapies.